Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Exe VP, Global Commercial Ops | April 28, 2010 | April 30, 2010 |
| Fresh Tracks Therapeutics, Inc.VICL · Entity 90076 | Director | May 23, 2018 | May 24, 2018 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 27, 2026 | May 29, 2026 |
| OTONOMY, INC.OTIC · Entity 116495 | Director | June 20, 2017 | July 14, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date April 28, 2010 · Filed April 30, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,889 |
Reported balance
After 2010-04-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2010-04-28 · Tax withholding · Disposed 1,401 · Balance 131,889 |
| Common StockSEC Table I · non-derivative | Direct | 130,488 |
Reported balance
After 2010-04-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2010-04-29 · Tax withholding · Disposed 1,401 · Balance 130,488 F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 2,717.7088 |
Reported balance
Holding disclosure · report date 2010-04-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,717.7088 F2: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of the date of this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of the date of this filing.
Fresh Tracks Therapeutics, Inc.
Report date May 23, 2018 · Filed May 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2028-05-22 | Direct | 6,500 |
Reported balance
After 2018-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-23 · Grant · Acquired 6,500 · Balance 6,500 F1: The date in this field is approximate. These options are exercisable at the date of the next annual meeting of stockholders. The date of the meeting has not been set, but is expected to occur in May 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The date in this field is approximate. These options are exercisable at the date of the next annual meeting of stockholders. The date of the meeting has not been set, but is expected to occur in May 2019.
NEUROCRINE BIOSCIENCES INC
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,567 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 2,567 · Balance 2,567 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: The RSUs will vest in full on May 27, 2027.
OTONOMY, INC.
Report date June 20, 2017 · Filed July 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.05 · Expires 2027-06-20 | Direct | 15,000 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option vest in full on the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the date of the Issuer's next annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALIGN TECHNOLOGY INC
Report date May 20, 2026 · Filed May 22, 2026
Section 16 reporting ended · disclosed 2026-05-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,036 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Exercise / conversion · Acquired 1,745 · Balance 5,036 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Exercise / conversion · Disposed 1,745 · Balance 0 F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 3,273 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,273 |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 22:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestriced Stock Unit · Derivative | 2,567 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001068754-26-000004 · wk-form4_1780092157.xml · derivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,567 Underlying: Common Stock · 2,567 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 27, 2027. F2 · derivative.expiration_date: The RSUs will vest in full on May 27, 2027. Read SEC document |
| May 21, 2026 Filed May 21, 2026 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 3,318 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001068754-26-000002 · wk-form4_1779405713.xml · derivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. Read SEC document |
| May 21, 2026 Filed May 21, 2026 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 3,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001068754-26-000002 · wk-form4_1779405713.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:07 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionRestricted Stock Units · Derivative | 1,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-237320 · ownership.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. F1 · derivative.exercise_date: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. F1 · derivative.expiration_date: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:07 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionCommon Stock | 1,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-237320 · ownership.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $47.89 | $0.00 |
DisclosureSEC source: 0001068754-25-000006 · wk-form4_1764192478.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $143.37 | $2,150,512.50 |
DisclosureSEC source: 0001068754-25-000006 · wk-form4_1764192478.xml · nonDerivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,068 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.51 to $144.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $47.89 | $718,350.00 |
DisclosureSEC source: 0001068754-25-000006 · wk-form4_1764192478.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2025 Filed May 22, 2025 21:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,869 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000128 · wk-form4_1747948800.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,869 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. F3 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. Read SEC document |
| May 22, 2025 Filed May 22, 2025 21:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,869 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000128 · wk-form4_1747948800.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 3,318 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000128 · wk-form4_1747948800.xml · derivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,318 Underlying: Common Stock · 3,318 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 21, 2026. F2 · derivative.expiration_date: The RSUs will vest in full on May 21, 2026. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | GrantRestricted Stock Units · Derivative | 1,745 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014204 · form4-05222025_090526.xml · derivative · entry 4 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,745 Underlying: Common Stock · 1,745 shares Expires not disclosed F1 · derivative.exercise_price: Represents par value of ALGN common stock. F3 · derivative.exercise_date: 100% of the RSUs granted on May 21, 2025 will become vested on the earlier of (i) May 21, 2026 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. F3 · derivative.expiration_date: 100% of the RSUs granted on May 21, 2025 will become vested on the earlier of (i) May 21, 2026 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionRestricted Stock Units · Derivative | 1,148 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014204 · form4-05222025_090526.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents par value of ALGN common stock. F2 · derivative.exercise_date: 100% of the restricted stock units ("RSUs") granted on May 22, 2024 vested on May 21, 2025 and shares were delivered to the Reporting Person. F2 · derivative.expiration_date: 100% of the restricted stock units ("RSUs") granted on May 22, 2024 vested on May 21, 2025 and shares were delivered to the Reporting Person. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionCommon Stock | 1,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014204 · form4-05222025_090526.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2024 Filed May 23, 2024 22:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 2,869 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000148 · wk-form4_1716502872.xml · derivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,869 Underlying: Common Stock · 2,869 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 22, 2025. F2 · derivative.expiration_date: The RSUs will vest in full on May 22, 2025. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:19 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | GrantRestricted Stock Units · Derivative | 1,148 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014475 · form4-05242024_080501.xml · derivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,148 Underlying: Common Stock · 1,148 shares Expires not disclosed F1 · derivative.exercise_price: Represents par value of ALGN common stock. F2 · derivative.exercise_date: 100% of the restricted stock units granted on May 22, 2024 will become vested on the earlier of (i) May 22, 2025 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. F2 · derivative.expiration_date: 100% of the restricted stock units granted on May 22, 2024 will become vested on the earlier of (i) May 22, 2025 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 4,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000134 · wk-form4_1716326089.xml · derivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 4,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000134 · wk-form4_1716326089.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:02 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionRestricted Stock Units · Derivative | 1,029 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014017 · form4-05212024_110547.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,029 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents par value of ALGN common stock. F2 · derivative.exercise_date: 100% of the restricted stock unit granted on May 17, 2023 became vested on May 17, 2024 and shares were delivered to the Reporting Person. F2 · derivative.expiration_date: 100% of the restricted stock unit granted on May 17, 2023 became vested on May 17, 2024 and shares were delivered to the Reporting Person. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:02 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionCommon Stock | 1,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014017 · form4-05212024_110547.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 21:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 20,000 | $39.79 Strike: $39.79 | $795,800.00 |
DisclosureSEC source: 0000914475-24-000094 · wk-form4_1710537915.xml · derivative · entry 6 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted September 30, 2015 and vests in 36 equal monthly installments. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 21:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 20,000 | $39.79 Strike: $39.79 | $795,800.00 |
DisclosureSEC source: 0000914475-24-000094 · wk-form4_1710537915.xml · derivative · entry 5 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted September 30, 2015 and vests in 36 equal monthly installments. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 21:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 20,000 | $139.41 | $2,788,278.00 |
DisclosureSEC source: 0000914475-24-000094 · wk-form4_1710537915.xml · nonDerivative · entry 4 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $137.83 to $142.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 21:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 20,000 | $39.79 | $795,800.00 |
DisclosureSEC source: 0000914475-24-000094 · wk-form4_1710537915.xml · nonDerivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 21:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 20,000 | $139.42 | $2,788,432.00 |
DisclosureSEC source: 0000914475-24-000094 · wk-form4_1710537915.xml · nonDerivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $137.87 to $142.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 21:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 20,000 | $39.79 | $795,800.00 |
DisclosureSEC source: 0000914475-24-000094 · wk-form4_1710537915.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2023 Filed May 31, 2023 21:07 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033137 · doc4.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 3,273 Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 4,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031111 · doc4.xml · derivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,199 Underlying: Common Stock · 4,199 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units will vest in full on May 17, 2024. F2 · derivative.expiration_date: The Restricted Stock Units will vest in full on May 17, 2024. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:25 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | GrantRestricted Stock Units · Derivative | 1,029 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031134 · doc4.xml · derivative · entry 4 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,029 Underlying: Common Stock · 1,029 shares Expires not disclosed F1 · derivative.exercise_price: Represents par value of ALGN common stock. F3 · derivative.exercise_date: 100% of the restricted stock unit granted on May 17, 2023 will become vested on the earlier of (i) May 17, 2024 or (i) the date of the 2024 annual meeting of stockholders. Shares will be delivered to reporting person on the vest date. F3 · derivative.expiration_date: 100% of the restricted stock unit granted on May 17, 2023 will become vested on the earlier of (i) May 17, 2024 or (i) the date of the 2024 annual meeting of stockholders. Shares will be delivered to reporting person on the vest date. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:25 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionRestricted Stock Unit · Derivative | 1,114 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031134 · doc4.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents par value of ALGN common stock. F2 · derivative.exercise_date: 100% of the restricted stock unit granted on May 18, 2022 became vested on May 17, 2023 and shares were delivered to reporting person. F2 · derivative.expiration_date: 100% of the restricted stock unit granted on May 18, 2022 became vested on May 17, 2023 and shares were delivered to reporting person. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:25 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionCommon Stock | 1,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031134 · doc4.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2022 Filed May 19, 2022 22:03 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | GrantRestricted Stock Units · Derivative | 1,114 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-030689 · doc4.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114 Underlying: Common Stock · 1,114 shares Expires not disclosed F3 · derivative.exercise_date: 100% of the restricted stock unit granted on May 18, 2022 will become vested on the earlier of (i) May 18, 2023 or (i) the date of the 2023 annual meeting of stockholders. Shares will be delivered to reporting person on the vest date. F3 · derivative.expiration_date: 100% of the restricted stock unit granted on May 18, 2022 will become vested on the earlier of (i) May 18, 2023 or (i) the date of the 2023 annual meeting of stockholders. Shares will be delivered to reporting person on the vest date. Read SEC document |
| May 18, 2022 Filed May 19, 2022 22:03 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionRestricted Stock Units · Derivative | 524 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-030689 · doc4.xml · derivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 524 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents par value of ALGN common stock. F2 · derivative.exercise_date: 100% of the restricted stock unit granted on May 19, 2021 became vested on May 18, 2022 and shares were delivered to reporting person. F2 · derivative.expiration_date: 100% of the restricted stock unit granted on May 19, 2021 became vested on May 18, 2022 and shares were delivered to reporting person. Read SEC document |
| May 18, 2022 Filed May 19, 2022 22:03 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionCommon Stock | 524 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-030689 · doc4.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 13,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 9,724 | $0.00 Strike: $84.95 | $0.00 |
DisclosureSEC source: 0001209191-22-030971 · doc4.xml · derivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,724 Underlying: Common Stock · 9,724 shares Expires 2032-05-18 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 18, 2022. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 20:36 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 252 | $708.93 | $178,650.86 |
DisclosureSEC source: 0001209191-21-049350 · doc4.xml · nonDerivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 12,749 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $708.805 to $708.98, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 20:36 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 3,248 | $707.95 | $2,299,421.60 |
DisclosureSEC source: 0001209191-21-049350 · doc4.xml · nonDerivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 13,001 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $707.08 to $708.655, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 20:36 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 1,500 | $705.74 | $1,058,610.00 |
DisclosureSEC source: 0001209191-21-049350 · doc4.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 16,249 F1 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $705.315 to $705.90, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 8,833 | $0.00 Strike: $92.35 | $0.00 |
DisclosureSEC source: 0001209191-21-034380 · doc4.xml · derivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 Underlying: Common Stock · 8,833 shares Expires 2031-05-19 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021. Read SEC document |
| May 19, 2021 Filed May 21, 2021 22:53 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | GrantRestricted Stock Unit · Derivative | 524 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035084 · doc4.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524 Underlying: Common Stock · 524 shares Expires not disclosed F1 · derivative.exercise_price: Represents par value of ALGN common stock. F3 · derivative.exercise_date: 100% of the restricted stock unit granted on May 19, 2021 will become vested on the earlier of (i) May 19, 2022 or (i) the date of the 2022 annual meeting of stockholders. Shares will be delivered to reporting person on the vest date. F3 · derivative.expiration_date: 100% of the restricted stock unit granted on May 19, 2021 will become vested on the earlier of (i) May 19, 2022 or (i) the date of the 2022 annual meeting of stockholders. Shares will be delivered to reporting person on the vest date. Read SEC document |
| May 19, 2021 Filed May 21, 2021 22:53 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionRestricted Stock Unit · Derivative | 1,271 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035084 · doc4.xml · derivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,271 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents par value of ALGN common stock. F2 · derivative.exercise_date: 100% of the restricted stock unit granted on May 20, 2020 became vested on May 19, 2021 and shares were delivered to reporting person on such vest date. F2 · derivative.expiration_date: 100% of the restricted stock unit granted on May 20, 2020 became vested on May 19, 2021 and shares were delivered to reporting person on such vest date. Read SEC document |
| May 19, 2021 Filed May 21, 2021 22:53 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionCommon Stock | 1,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035084 · doc4.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 01:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 479 | $628.52 | $301,061.08 |
DisclosureSEC source: 0001209191-21-008630 · doc4.xml · nonDerivative · entry 7 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,478 F7 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $628.33 to $628.54, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 01:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 1,121 | $627.46 | $703,382.66 |
DisclosureSEC source: 0001209191-21-008630 · doc4.xml · nonDerivative · entry 6 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,957 F6 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $627.05 to $628.30, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 01:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 3,337 | $626.71 | $2,091,331.27 |
DisclosureSEC source: 0001209191-21-008630 · doc4.xml · nonDerivative · entry 5 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,078 F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $626.03 to $627.00, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 01:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 3,657 | $625.02 | $2,285,698.14 |
DisclosureSEC source: 0001209191-21-008630 · doc4.xml · nonDerivative · entry 4 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,415 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $624.77 to $625.59, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 01:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 507 | $623.92 | $316,327.44 |
DisclosureSEC source: 0001209191-21-008630 · doc4.xml · nonDerivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,072 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $623.66 to $624.65, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 01:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 1,101 | $622.98 | $685,900.98 |
DisclosureSEC source: 0001209191-21-008630 · doc4.xml · nonDerivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,579 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $622.70 to $623.11, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 01:11 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 4,798 | $622.19 | $2,985,267.62 |
DisclosureSEC source: 0001209191-21-008630 · doc4.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,680 F1 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $621.35 to $622.32, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2020 Filed Nov 4, 2020 23:57 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 5,000 | $480.03 | $2,400,161.50 |
DisclosureSEC source: 0001209191-20-057000 · doc4.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,478 F1 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $479.00 to $481.57, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.